<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> are not uncommon in patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study sought to determine the incidence of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> compared with the general population, and to characterise their clinical and pathological features </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients diagnosed with <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> between January 1992 and December 2007 were identified from the databases of <z:hpo ids='HP_0002861'>Melanoma</z:hpo> Institute Australia (MIA) and the Department of Tissue Pathology and Diagnostic <z:hpo ids='HP_0002664'>Oncology</z:hpo>, Royal Prince Alfred Hospital (RPAH) </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical histories of the patients in the MIA database and pathology reports in the RPAH archives were reviewed </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence risk for <z:hpo ids='HP_0002861'>melanoma</z:hpo> and non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was obtained from Australian <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Incidence and Mortality registry data </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of 18,226 patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo>, 55 (0.3%) had <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> was diagnosed subsequent to <z:hpo ids='HP_0002861'>melanoma</z:hpo> in 23 (41.8%) patients, prior to <z:hpo ids='HP_0002861'>melanoma</z:hpo> in 7 (12.7%) patients, and concurrently with <z:hpo ids='HP_0002861'>melanoma</z:hpo> in 25 (45.5%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>53 (96.4%) patients developed non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), the most common subtypes being <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (49.1%), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (23.6%) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (16.4%) </plain></SENT>
<SENT sid="8" pm="."><plain>Two (3.6%) patients developed Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002861'>Melanoma</z:hpo> patients had a significantly higher risk of developing NHL than the general population (standardised incidence rate 3.5) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: A small but significant proportion of patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> develop <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, either synchronously or metachronously </plain></SENT>
<SENT sid="11" pm="."><plain>Lymph node specimens from <z:hpo ids='HP_0002861'>melanoma</z:hpo> patients might harbour <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and might represent the first recognised site of disease </plain></SENT>
<SENT sid="12" pm="."><plain>A high index of suspicion for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> when evaluating lymph nodes from patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> will ensure prompt diagnosis and appropriate management </plain></SENT>
</text></document>